Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400931 | 0.85 | SLC6A2 (0.65) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL406390 | 0.84 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL407501 | 0.82 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3CYP2D6TAAR1 | |
| SCHEMBL406615 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2A | |
| SCHEMBL401681 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL406641 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL401682 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL405098 | 0.78 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2A | |
| SCHEMBL10123517 | 0.78 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3CYP2D6TAAR1 | |
| SCHEMBL407649 | 0.78 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP2D6TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285787-B1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-8404730-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-02-23 | — | — | US | disclosed |
| US-8101642-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-01-24 | — | — | US | disclosed |
| EP-2285787-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-23 | — | — | EP | disclosed |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2010-12-09 | — | — | US | disclosed |
| WO-2009148290-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | ADRB3, PNMT, OPRK1 | SLC6A4 47/4885SLC6A2 31/4885SLC6A3 7/4885 |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | ADRB3, PNMT, OPRK1 | SLC6A4 47/4885SLC6A2 31/4885SLC6A3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.